API | otenabant

otenabant Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesity, but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant. ^Wikipedia

Chemistry

SMILES: CCNC1(CCN(CC1)c2ncnc3c2nc(c4ccccc4Cl)n3c5ccc(Cl)cc5)C(=O)N
InChIKey: UNAZAADNBYXMIV-UHFFFAOYSA-N
Mol. Mass: 510.43
ALogP: 4.22 Partition coefficient
ChEMBL Molecule:
otenabant

More Chemistry

Pharmacology

Mechanism of Action:
- Cannabinoid receptor 1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1-(9-(4-chlorophenyl)-8-(2-chlorophenyl)-9h-purin-6-yl)-4-ethylaminopiperidine-4-carboxylic acid amide | cp945598 | cp 945598 | cp-945598 | cp-945,598 | cp-945598-01 | otenabant | otenabant hcl

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Obesity

Experimental Indications - Clinical Trial Phases 1-4 (4)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 1)

Obesity (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue